Altimmune Inc (NASDAQ:ALT)

0.708
Delayed Data
As of Apr 20
 -0.0492 / -6.50%
Today’s Change
0.68
Today|||52-Week Range
8.20
-64.42%
Year-to-Date
SECTOR
Commercial Services
INDUSTRY
Miscellaneous Commercial Services
MARKET CAP
$27.4M

Company Description

Altimmune, Inc. is a clinical stage company, which engages in the research and development of immunotherapeutic products. Its portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Contact Information

Altimmune, Inc.
910 Clopper Road
Gaithersburg Maryland 20878
P:(240) 654-1450
Investor Relations:

Employees

Shareholders

Individual stakeholders43.29%
Mutual fund holders3.22%
Other institutional10.47%

Top Executives

William EnrightPresident, Chief Executive Officer & Director
Elizabeth Adkins CzerepakCFO, Secretary & EVP-Corporate Development
M. Scot RobertsChief Scientific Officer
Sybil TaskerChief Medical Officer & SVP-Clinical Research
Bertrand GeorgesChief Technology Officer